Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 8 3 2014 09 15 1 11 Arash Jalali Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. AND Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran. Kamran Alimoghaddam Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran. Mahmood Mahmoudi Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Kazem Mohammad Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Hojjat Zeraati Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Seied Asadollah Mousavi Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran. Babak Bahar Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran. Mohammad Vaezi Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran. Mohammad Jahani Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran. Ardeshir Ghavamzadeh Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran. 2015 10 14 The aim of this study was to assess the predictive effect of the EBMT risk score on the outcomes of allogeneic stem cell transplantation in a relatively homogenous group of acute myelogenous leukemia (AML) patients regarding the occurrence of acute and chronic graft versus host disease (GVHD). This historical cohort study included adult patients (≥ 15 years old) with AML (n=363) who received allogeneic peripheral blood stem cell transplantation from HLA-identical sibling donors in the first or higher complete remission following myeloablative conditioning regimens between 2004 and 2011.The patients recruited in this study were followed-up until January 2013. Patients with acute promyelocytic leukemia (APL) were excluded from the study. Early outcomes until day +100 and events after day +100 were regarded for acute and chronic GVHD, respectively. A multi state model for competing risks was applied. We found that the EBMT risk score was a good predictor for overall survival (OS) and relapse incidence; however, it was not associated with transplant-related mortality (TRM). The EBMT risk score was not associated with acute and chronic GVHD. For early outcomes, the predictive effect of the EBMT risk score was not statistically significant in the presence of acute GVHD; however, in the presence of chronic GVHD, it was a significant predictor of relapse but not for TRM. It seems that the effect of EBMT risk score on OS and relapse incidence cannot be affected by GVHD. Although the results were insignificant, there was evidence that the EBMT risk score can predict early outcomes, while for late outcomes, it works well for relapse and OS but not for TRM. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/419 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/419/378

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 8 3 2014 09 15 12 19 Vahid Lesan Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. AND Department of Biology, Faculty of Food Industry and Agriculture, Standard Research Institute (SRI), Karaj, Iran. Seyed Ghaffari Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. Jamile Salaramoli Department of Basic Science, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran. Mansour Heidari Stem Cell Preparation Unit, Eye Research Center, Farabi Hospital, Tehran University of Medical Sciences, Tehran, Iran. Masoumeh Rostami Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. Kamran Alimoghaddam Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. Ardeshir Ghavamzadeh Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. 2015 10 14 Metformin has recently been introduced as an anti-cancer agent. In this study, we evaluated the effect of metformin and metformin/cisplatin on human gastric MKN-45 cell line. When we used metformin alone, it could inhibit proliferation and induce apoptosis, but it diminish anti-proliferative effects of cisplatin when they are used in combination. Further, we checked mRNA levels of survivin, mTOR, and Akt by real-time PCR. When MKN-45 cells were treated with metformin/cisplatin, the expression of survivin and mTOR were increased. The antagonistic effect of metformin on cisplatin could be through survivin and mTOR signaling pathways. Our results also suggest that interfering effect of metformin on cisplatin may be also through upregulation of Akt. Regarding the pivotal role of Akt in drug resistance, it may be reasonable to conclude that the antagonistic effect of metformin on cisplatin effect may be through this central mediator of drug resistance. Taken together, it seems that metformin is not a good option for sensitizing MKN-45 cell line to cisplatin, and in co-prescription of metformin and cisplatin in gastric cancer patients who suffer diabetes type 2, it should be highly cared. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/418 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/418/379

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 8 3 2014 09 15 20 23 Mohammad Ali Mashhadi Health promotion research center, Zahedan University of Medical Sciences, Zahedan, Iran. Mahmoud Ali Kaykhaei Department of Internal medicine, Zahedan University of Medical Sciences, Zahedan, Iran. Mahdi Mohammadi Health promotion research center, Zahedan University of Medical Sciences, Zahedan, Iran. Mahdi Hashemi Department of Internal medicine, Zahedan University of Medical Sciences, Zahedan, Iran. Tahereh Mohammadi Fatideh Department of Internal medicine, Zahedan University of Medical Sciences, Zahedan, Iran. 2015 10 14 Introduction: Imatinib, a tyrosine kinase inhibitor which resulted in much improvement in the treatment of chronic myelogenous leukemia (CML), may adversely affect thyroid gland function. To date, assessment of thyroid function during imatinib therapy has limited to retrospective studies. The aim of this study was to evaluate the effects of imatinib on thyroid function in a prospective manner. Materials and Methods: In this prospective study, 16 newly diagnosed adult subjects with positive Philadelphia chromosome in chronic phase of CML without any other apparent underlying diseases were enrolled. Free T3, Free T4, TSH, Anti TPO and Anti thyroglobulin antibodies were measured before and after 4 and 12 weeks of treatment. Results: Of the 16 patients, 9 were male (57.1%) and 7(42.9%) were female with a mean age of 29±5 years. There were statistically significant changes within reference ranges in serum concentrations of TSH (P=0.753 and 0.002), Free T3 (P=0.012 and 0.007) and Anti Thyroglobulin (P=0.221 and 0.041) 1 month before and 3 months after imatinib initiation, respectively. At the same time, there were no significant changes in serum Free T4 (P=0.196 and 0.650) and Anti TPO (P=0.807 and 0.600) concentrations. Conclusion: This study showed some significant changes on thyroid function tests during imatinib therapy. However, all of them were within the normal range without any clinical abnormalities in the course of treatment. We recommend other studies with larger sample size and longer duration of follow-up. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/417 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/417/380

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 8 3 2014 09 15 24 29 Zohreh Sanaat Hematology & Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Reza Khalili Hematology & Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Shohreh Almasi Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Mohammad Reza Aliparasti Hematology & Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Seyed-Mohammad Tavangar Pathology department, shariati hospital, Tehran University of Medical Science, Tehran, Iran. Aliakbar Movasaghpoor Hematology & Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Fariba Kazemi Hematology & Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Arash Davani Basic research team, KUMC Cardiovascular Research Institute, Kansas city, Kansas, USA. 2015 10 14 Introduction: Acute Myeloid Leukemia is a malignant transformation of hematopoietic tissue, bone marrow infiltration of undifferentiated cells known as blasts that interfere with the production of normal cells. Vascular endothelial growth factor (VEGF) is persistently secreted from myeloid cells and high levels can be detected in patients' serum. Methods: Twenty-one AML patients, who were chemotherapy candidates were evaluated in a clinical trial. Serum VEGF was measured by ELISA. VEGFA, VEGFC mRNA and bone marrow MVD were measured in all patients before and after chemotherapy and then all results were analyzed. Results: There were 10 (48%) female and 11(52%) male patients ranged in age from 20 to 60 years, with an average age of 39.5 ±14.1 years. The mean amount of MVD was reduced from 10.8±3.6 before chemotherapy to7.6±3.3 after chemotherapy (P=0.008). VEGF was also reduced from 0.59±0.16 before chemotherapy to 0.24±0.03 after chemotherapy (P=0.005). Gene expression differences for VEGFA mRNA was 4.6±1.4, while it was 120.7±93.2 for VEGFC mRNA, showing the significance only for VEGA mRNA (P=0.02). Conclusion: Regarding reduced angiogenesis, we can conclude that anti-angiogenic preparations can be effective in treatment course of AML in combination with chemotherapy regimen. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/416 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/416/381

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 8 3 2014 09 15 30 36 Sajedeh Saeidi Health research institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Kaveh Jaseb Health research institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Ali Amin Asnafi Health research institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Fakher Rahim Health research institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Fatemeh Pourmotahari Department of Biostatistics and Epidemiology, School of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Samira Mardaniyan Department of Biostatistics and Epidemiology, School of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Homayoon Yousefi Health research institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Arash Alghasi Health research institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Mohammad Shahjahani Health research institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Najmaldin Saki Health research institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 2015 10 14 Background: Immune thrombocytopenic purpura (ITP) is an autoimmune disease that can cause bleeding disorders in patients, and presents in acute and chronic forms. The acute form is frequently seen in children, but the chronic form mainly inflicts adults. There are differences and similarities in clinical and laboratory findings of the disease between children and adults. We study these differences and similarities in these two groups of patients with ITP. Methods: In this study, we retrospectively evaluated the clinical and laboratory data of 323 ITP cases within three years. None of our patients had a history of thrombocytopenia. Patients were classified into two groups of children (3 months to 16 years of age) and adults (≥ 16 years). Data analysis was conducted using SPSS software, and the analysis results were compared between the two age groups. Results: Overall, the disease prevalence was higher in women than men, but the prevalence of childhood ITP was higher in males than females. The prevalence of initial symptoms including petechiae, purpura and ecchymosis was 60.5% and 61%, respectively in all patients, but severe bleeding rarely occurred in patients (28.8%). 30.5% of patients had a history of infection before developing ITP, and the children had a higher frequency of infection (80.8%). Before treatment, the mean platelet count in adults and children was 33000/μL and 35000/μL, respectively. Conclusion: Comparison of data in children and adults with ITP indicated similarities and differences in clinical and laboratory findings between the two groups with differences in prevalence, bleeding symptoms, initial platelet count and infection history. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/415 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/415/382

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 8 3 2014 09 15 172 185 EN Shaban Alizadeh Hematology Department, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran Seyed Ghader Azizi Hematology Department, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran Masoud Soleimani Hematology Department, School of Medicine, Tarbiat Modares University, Tehran, Iran Yadollah Farshi Hematology Department, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran Zahra Kashani khatib Hematology Department, School of Medicine, Tarbiat Modares University, Tehran, Iran 2015 10 18 2015 12 17 MiRs are 17-25 nucleotide non-coding RNAs. These RNAs target approximately 80% of protein coding mRNAs. MiRs control gene expression and altered expression of them affects the development of cancer. MiRs can function as tumor suppressor via down-regulation of proto-oncogenes and may function as oncogenes by suppressing tumor suppressors. Myeloproliferative neoplasias (formerly known as chronic myeloproliferative disorders) form a class of hematologic malignancies demonstrating the expansion of stem cells in one or more hematopoietic cell lines. CML results from an acquired translocation known as BCR-ABL (Philadelphia chromosome). JAK2V617F mutation is present in over 95% of PV, 55% of ET and 65% of PMF cases. Aberrant expression of miR is associated with myeloproliferative neoplasias, pathogenesis, disease progress and response to treatment. MiRs can also be potential therapeutic targets. CML is mainly treated by tyrosine kinase inhibitors such as Imatinib. In addition, altered function of miRs may be used as a prognostic factor in treatment. Resistance to Imatinib is currently a major clinical problem. The role of a number of miRs has been demonstrated in this resistance. Changing expression pattern of miRs can be effective in response to treatment and inhibition of drug resistance. In this paper, we set out to evaluate the effect of miRs in pathogenesis and treatment of MPN. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/476 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/476/508

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 10 3 2016 06 28 186 190 EN Ratnam Nookala Department of Hematology-Oncology, Prince George’s Medical Center, Cheverly, Maryland, USA Vera Batchu Department of Hematology-Oncology, Prince George’s Medical Center, Cheverly, Maryland, USA Heather